Attached files
| file | filename |
|---|---|
| EX-23.1 - EX-23.1 - Sagent Pharmaceuticals, Inc. | d121715dex231.htm |
| EX-21.1 - EX-21.1 - Sagent Pharmaceuticals, Inc. | d121715dex211.htm |
| EX-31.1 - EX-31.1 - Sagent Pharmaceuticals, Inc. | d121715dex311.htm |
| EX-31.2 - EX-31.2 - Sagent Pharmaceuticals, Inc. | d121715dex312.htm |
| EX-32.1 - EX-32.1 - Sagent Pharmaceuticals, Inc. | d121715dex321.htm |
| 10-K - FORM 10-K - Sagent Pharmaceuticals, Inc. | d121715d10k.htm |
Exhibit 23.2
Consent of Independent Auditors
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-200027) of Sagent Pharmaceuticals, Inc. |
| (2) | Registration Statement (Form S-8 No. 333-175352) pertaining to the 2007 Global Share Plan of Sagent Holding Co. and the 2011 Incentive Compensation Plan of Sagent Pharmaceuticals, Inc. |
of our report dated March 7, 2016, with respect to the financial statements of Sagent Agila LLC., included in the Annual Report (Form 10-K) of Sagent Pharmaceuticals, Inc. for the year ended December 31, 2015.
/s/ Ernst and Young LLP
Chicago, Illinois
March 7, 2016